Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Biogen ( (BIIB) ) just unveiled an announcement.
On February 11, 2026, Biogen announced that Caroline Dorsa, Chair of the company’s Board of Directors, will not stand for re-election at the 2026 Annual Meeting of Stockholders. The company stated that Dorsa’s decision is not related to any disagreement with the board or Biogen regarding its operations, policies or practices, suggesting an orderly and non-contentious board transition for stakeholders.
The most recent analyst rating on (BIIB) stock is a Buy with a $236.00 price target. To see the full list of analyst forecasts on Biogen stock, see the BIIB Stock Forecast page.
Spark’s Take on BIIB Stock
According to Spark, TipRanks’ AI Analyst, BIIB is a Neutral.
BIIB scores as a mid-range opportunity driven primarily by stable financials (profitability, free cash flow, and manageable leverage). The earnings outlook is mixed: growth products and pipeline progress are positives, but 2026 revenue is guided down with ongoing legacy MS erosion and timing/reimbursement risks. Technically the trend is strong but appears overbought, while valuation is not especially cheap at ~22.8x earnings and lacks a dividend yield input.
To see Spark’s full report on BIIB stock, click here.
More about Biogen
Biogen Inc. is a biotechnology company focused on discovering, developing and delivering therapies for neurological and neurodegenerative diseases. The company operates in the biopharmaceutical industry and markets treatments aimed at conditions such as multiple sclerosis and other serious neurological disorders worldwide.
Average Trading Volume: 2,002,179
Technical Sentiment Signal: Hold
Current Market Cap: $28.44B
See more data about BIIB stock on TipRanks’ Stock Analysis page.